Luforbec 200/6 mdi® (formeterol/beclometasone)

Clinical Indication

Treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate


At the request of the Respiratory Prescribing Group for formulary reasons.

Date of classification

January 2023

Do not prescribe

Drugs not recommended for use in LLR because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.